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Salvage Radical Prostatectomy in Nonmetastatic
Castration-resistant Prostate Cancer Patients Who
Received Previous Radiotherapy: A Feasibility Study
Nonmetastatic castration-resistant prostate cancer (NM-
CRPC) refers to a rising prostate-specific antigen (PSA) level
under androgen-deprivation therapy (ADT), with testoster-
one <50 ng/ml in the absence of clinically detectable
metastatic disease. It is mostly the result of widespread off-
label use of primary or salvage ADT in patients with PSA
progression in the absence of metastases. The natural
history of this disease suggests that only 30% of cases will
develop bonemetastases and 20%will die within 2 yr [1]. At
present, no treatment option outside the setting of a clinical
trial is recommended for NM-CRPC [2], making the
management of this clinical entity a therapeutic challenge.
We assessed the role of salvage radical prostatectomy
(sRP) and extended lymphadenectomy in a prospective
feasibility study of 12 patients with NM-CRPC following
primary radiotherapy. The studywas approved by the ethics
committee of the San Giovanni Battista Hospital in Torino,
Italy, on April 20, 2009. Castration-resistant prostate cancer
(PCa) was defined as PSA >2 ng/ml of the nadir value [3].
Evidence of bone metastases and/or retroperitoneal disease
at bone scan, computed tomography (CT), or positron
emission tomography (PET)-CT and a PSA density velocity
<6 mo represented exclusion criteria. Local failure was
defined by digital rectal examination, PET-CT, or biopsy.
Patient characteristics are detailed in Table 1.
At baseline, five patients had intermediate-risk PCa and
seven had high-risk PCa. Median time from primary
treatment to the development of NM-CRPC was 49 mo
(range: 2–104 mo). Median PSA at salvage surgery was
6.3 ng/ml (interquartile range: 3.0–8.8 ng/ml). On patho-
logic specimen, 11 patients had pT3/pT4 disease, 7 had
positive margins, and 6 were pN1. Moreover, 10 patients
had Gleason score 9 (n = 8) or 10 (n = 2) after sRP. ADT was
stopped postoperatively in 10 of 12 patients. PSA nadir
<0.2 ng/mlwas achieved in six patients. At amedian follow-
up of 40.5 mo, 3 of 12 patients had no evidence of disease, 1
showed biochemical failure only, 2 developed metastatic
disease, and 6 died of disease. Comparative Kaplan-Meier
curves failed to show a significant difference in cancer-
specific survival for patients who achieved the PSA nadir
and those who did not.
Major complications were rectal injury requiring tem-
porary colostomy in one patient and rectourethral fistula
eventually needing pelvic exenteration plus terminal
colostomy in another patient. Urinary continence was
achieved in seven patients, one remained heavily inconti-
nent, and four required some sort of urinary diversion
(bilateral nephrostomy and indwelling catheter, each in one
patient, and two ileal conduits).
Our preliminary results show that sRP is feasible for
NM-CRPC patients, with an expected complication rate that
may be higher than that reported for sRP in hormone-naı¨ve
PCa [4]. This is likely to reflect themore aggressive nature of
E U RO P E AN URO L OG Y 6 5 ( 2 0 1 4 ) 2 5 4 – 2 6 2
avai lable at www.sciencedirect .com
journal homepage: www.europeanurology.com
Table 1 – Patient characteristics at baseline (preradiotherapy) and
at the time of nonmetastatic castration-resistant prostate cancer
(presurgery)
Characteristic Result
PSA at diagnosis of primary PCa, ng/ml, medial (IQR) 12.4 (4.9–131)
Initial (biopsy) Gleason score
7 6
8 3
9 3
PSA at salvage RP, ng/ml, median (IQR) 6.3 (3.0–8.8)
Age at salvage RP, yr, median (range) 66.5 (54–73)
Time to NM-CRPC, mo, median (range) 49 (2–104)
Extent of pelvic LND
Limited LND 1
Extended LND 9
Retroperitoneal LND 1
No LND possible 1
No. of nodes removed, median (range) 21 (0–52)
No. of positive nodes, median (range) 3 (0–46)
pT Stage
pT2 1
pT3a 3
pT3b 6
pT4 2
pN Stage
pN0 5
pN1 6
pNx 1
Final Gleason score
7 2
9 8
10 2
IQR = interquartile range; LND = lymph node dissection; NM-CRPC =
nonmetastatic castration-resistant prostate cancer; PCa = prostate cancer;
PSA = prostate-specific antigen; RP = radical prostatectomy.
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hormone-refractory disease, as documented by the high
proportion of locally advanced or node-metastatic disease
and Gleason score 9–10 on pathologic specimen. SRP may
positively affect the natural history of the disease in some
patients, as shown by the initial PSA response in one of two
cases and by disease-free status in one of four patients.
Selection criteria, mainly PSA kinetics cut-off points [1], are
mandatory to identify the subgroup of patients who are
more likely to benefit from surgery for an otherwise lethal
disease such as NM-CRPC.
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The New Promise of FACBC Position Emission
Tomography/Computed Tomography in the Localization
of Disease Relapse After Radical Treatment for Prostate
Cancer: Are We Turning to the Right Radiotracer?
The biochemical relapse (BCR) of prostate cancer (PCa) after
radical treatment precedes the clinical disease by many
years, but localizing the site of recurrence is a challenge.
Positron emission tomography/computed tomography
(PET/CT) with 11C- or 18F-choline is the most accurate
technique in the assessment of PCa relapse [1], and it can
detect the site of disease recurrence even with a very low
prostate-specific antigen (PSA) level [2]. Unfortunately,
choline PET/CT can detect only half of the PCa lesions
because of the slow proliferation of PCa cells that reflects a
slowmembrane metabolism with a resulting small amount
of choline uptake [3]. For this reason, some metastatic
deposits >10 mm may be negative at choline PET/CT scan.
Fortunately, research in the field of molecular imaging
never stops, and new radiotracers are now under evalua-
tion. In recent years, a synthetic L-leucine analog (anti-1-
amino-3-18F-fluorocyclobutane-1-carboxylic acid [FACBC])
hasbeenproposedasapossible radiotracer forPCa [4]. FACBC
uptake is related to the functional activity of two different
amino acid transporters, and the distribution of the tracer
in the body is more favorable than choline: The uptake of
FACBC in the kidney is negligible, and no activity is found in
the urinary tract. Other advantages of FACBC are the short
synthesis time and a long half-life, which eliminate the
need for an onsite cyclotron, rendering the technique more
available. Above all, the first clinical studies showed very
promising and reproducible results. Improvement in the
detection rate is about 20–30% in comparison with other
imaging techniques, making FACBC the possible radiotracer
of the future for PCa [4,5].
In a recent paper published in the European Journal of
Nuclear Medicine and Molecular Imaging, our group com-
pared FACBC PET/CTwith 11C-choline PET/CT in 15 patients
with BCR after radical prostatectomy andwithout androgen
deprivation therapy (mean PSA level at time of enrollment:
2.1  2 ng/ml) [5]. We found better detection rates with
FACBC for patient analysis (40% vs 20%) as well as lesion
analysis. In particular, every lesion detected with 11C-choline
was also visualized with FACBC, but FACBC found twice as
many positive patients and positive lesions than 11C-choline
in the bones, lymph nodes, and prostatic fossa, indicating that
FACBCmay be superior to 11C-choline for the identification of
PCa cells. Last but not least, the images obtained with FACBC
were dramatically more clear and evident than those obtained
with 11C-choline, with a superior target-to-background ratio
for FACBC in all lesions. We confirmed our results in a series of
E U RO P E AN URO L OGY 6 5 ( 2 0 1 4 ) 2 5 4 – 2 6 2 255
